IP Library Granted Patent US 9,872,843
Granted Patent B2
US 9,872,843 · App. 14/350,322 · Granted Jan 23, 2018

Antimicrobial compositions and methods employing same

Inventor: Matthew Franco Myntti (St. Augustine, FL)
Assignee: Next Science, LLC
A61K31/194A01N25/02A01N25/08A01N37/36A01N61/00A61K8/19A61K8/365A61K8/39A61K8/41A61K8/416A61K8/44A61K8/463A61K8/466A61K8/4926A61K8/4973A61K8/55A61K8/602A61K8/86A61K9/0014A61K9/0063A61K9/06A61K31/14A61K31/19A61K33/00A61K33/02A61K33/04A61K33/20A61K33/24A61K33/32A61K33/42A61K47/02A61K47/10A61K47/12A61K47/34A61L26/0066A61Q17/005A61K9/08A61L2300/404A61Q11/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,872,843
App. No.
14/350,322
Granted
Jan 23, 2018
Kind
B2
Abstract

An aqueous composition with a higher-than-neutral pH includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. This composition, as well as an acidic counterpart and solid materials, can be used in a variety of applications such as wound care, oral care, medical equipment reprocessing, healthcare acquired infection and implant treatment.

Claims (20)

1. A process for treating a microbe-induced condition of the oral cavity of a subject in need thereof, said process comprising administering to said subject an oral care composition having a pH of from 7.5 to 10 and an osmolarity of from 1.25 to 2.5 Osm/L, said oral care composition consisting of (1) an oral rinse containing eucalyptol, thymol, menthol, and methyl salicylate in an alcohol vehicle, (2) an aqueous composition consisting of dissociation products of at least one base and a phosphate or sulfate in water, and (3) from 0.5 to 1.8 g/L of at least one cationic surfactant.

2. The process of claim 1 wherein said oral care composition has an osmolarity of from 1.33 to 2.25 Osm/L.

3. The process of claim 2 wherein said oral care composition has an osmolarity of from 1.5 to 2 Osm/L.

4. The process of claim 3 wherein said oral care composition has an osmolarity of 1.75±0.075 Osm/L.

5. The process of claim 1 wherein said oral care composition has a pH of from 7.7 to 9.8.

6. The process of claim 5 wherein said oral care composition has a pH of about 9±0.5 pH units.

7. The process of claim 1 wherein from 0.75 to 1.5 g/L of said at least one cationic surfactant is present in said oral care composition.

8. The process of claim 7 wherein from 0.8 to 1.4 g/L of said at least one cationic surfactant is present in said oral care composition.

9. The process of claim 1 wherein said at least one cationic surfactant comprises cetylpyridinium chloride.

10. The process of claim 1 wherein said at least one cationic surfactant is cetylpyridinium chloride.

11. The process of claim 1 wherein said oral care composition is administered for inhibiting onset of a microbe-induced condition of the oral cavity of said subject.

12. The process of claim 1 wherein said oral care composition is administered for treating an existing dental or gum disease in the oral cavity of said subject.

13. The process of claim 1 wherein said oral care composition is administered after said subject has had a dental implant introduced to said oral cavity.

14. The process of claim 6 wherein said oral care composition has a pH of 9±0.3 pH units.

15. A process for treating a microbe-induced condition of the oral cavity of a subject in need thereof, said process comprising administering to said subject an oral care composition having a pH of from 7.5 to 10 and an osmolarity of from 1.5 to 2 Osm/L, said oral care composition consisting of (1) an oral rinse containing eucalyptol, thymol, menthol, and methyl salicylate in an alcohol vehicle, (2) an aqueous composition consisting of dissociation products of an alkali metal hydroxide and a phosphate in water, and (3) from 0.5 to 1.8 g/L of cetylpyridinium chloride.

16. The process of claim 15 wherein said phosphate is a dihydrogen phosphate salt.

17. The process of claim 15 wherein said oral care composition has a pH of 9±0.3 pH units.

18. The process of claim 15 wherein from 0.75 to 1.5 g/L of cetylpyridinium chloride is present in said oral care composition.

19. The process of claim 18 wherein from 0.8 to 1.4 g/L of said at least one cationic surfactant is present in said oral care composition.

20. The process of claim 15 wherein said oral care composition has an osmolarity of 1.75±0.075 Osm/L.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2025
From: NEXT SCIENCE IP HOLDINGS PTY LTD
To: OSARTIS GMBH
Reel/Frame 072590/0763 →
NUNC PRO TUNC ASSIGNMENT Recorded Mar 24, 2018
From: NEXT SCIENCE, LLC
To: NEXT SCIENCE IP HOLDINGS PTY LTD
Reel/Frame 045344/0297 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2015
From: MYNTTI, MATTHEW F., DR.
To: NEXT SCIENCE, LLC
Reel/Frame 034836/0186 →
Continuity (3)
Provisional Application 61545108 · Oct 8, 2011
Provisional Application 61660649 · Jun 15, 2012
Related Publication 20140242188A1 · Aug 28, 2014